Phase Appropriate Quality Oversight for Cell and Gene Therapy
- This event has passed.
Thank YOU ANNUAL SPONSORS
PDA Midwest Chapter invites you to learn about phase appropriate quality oversight for cell and gene therapy
In the growing field of Cell and Gene Therapy, the question of what appropriate Quality Oversite at various clinical phases should be. Too little oversight can affect the quality and robustness of the product. Too much oversight stalls innovation and creates unnecessary hurdles that may be difficult to overcome when developing quality systems and controls for investigational cell and gene therapies. As Cell & Gene Therapies are administered to patients in all phases of trials, clinical supplies must be manufactured under conditions that meet cGMP requirements appropriate for the phase of manufacturing.
Presentation Date and Time
Wednesday, November 16, 2022 @ 11:00 am (central time zone)
|Opening, Presenter Introduction||11:00am – 11:10am*|
Speaker – Andrea M. Biggs,
Director of Quality – Cell & Gene Therapy, Pharma Services Group of ThermoFisher Scientific
|11:10 am – 11:45am*|
|Q&A From Audience to Presenter||11:45am – 12:00pm*|
|*Central time zone|
Thanks to our sponsor, general admission is FREE
Click the link below to register for this event
The PDA Midwest Chapter is very grateful to our dedicated members and sponsors for their continued interest, participation and support. We truly appreciate the generosity of our sponsors over the years, for without you, we could not provide this level of activity for our members.
- 2-minute pre-recorded commercial video during the webinar
- Recognition in email/social media correspondence of webinar